Shareholders Approve Reverse Stock Split Authority (1:5 to 1:50) and 1.85M Share Equity Plan Increase
GNPX sits 38% above its 52-week low of $0.423 on elevated volume (2.1× avg).
Summary
Genprex shareholders approved a reverse stock split authority (1:5 to 1:50) to address Nasdaq delisting threats and authorized an additional 1.85 million shares for the equity incentive plan, posing significant potential dilution.
Key Events · Corporate Governance and Compliance · GNPX
-
Reverse Stock Split Authority Approved
Shareholders authorized the Board to implement a reverse stock split at a ratio between 1:5 and 1:50 until December 31, 2027. This is a critical step to address the Nasdaq delisting notice received on June 12, 2026, for failing to meet the $1.00 minimum bid price.
-
Equity Incentive Plan Expanded
The amended 2018 Equity Incentive Plan was approved, increasing the authorized shares for issuance by an additional 1,850,000 shares. This represents a potential dilution of approximately 17.5% based on the company's current market capitalization.
Analysis · GNPX · Life Sciences
Genprex shareholders approved a broad reverse stock split authority (1:5 to 1:50), a critical step for the company to regain compliance with Nasdaq's minimum bid price requirement following a recent delisting notice. While necessary for continued listing, reverse splits are often viewed negatively by the market. Additionally, shareholders approved an increase of 1,850,000 shares for the equity incentive plan, representing substantial potential dilution of approximately 17.5% based on current market capitalization, adding further pressure on existing shareholders.
At the time of this filing, GNPX was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $0.42 to $55.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.